A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework

Value in Health

Volumn 16, Issue 1, 2013, Pages 66-75

  Sadatsafavi, Mohsen ^a   Marra, Carlo ^a   Marra, Fawziah ^a   Moran, Onofre ^b   Fitzgerald, J Mark ^a   Lynd, Larry ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

benefit risk analysis; decision uncertainty; quality adjusted life years; tuberculosis

Indexed keywords

ISONIAZID; LIVER ENZYME;

ARTICLE; BCG VACCINATION; CANADA; DRUG EFFICACY; DRUG FEVER; HEADACHE; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; HYPERTRANSAMINASEMIA; INFECTION RISK; LATENT TUBERCULOSIS; LIVER TOXICITY; MALAISE; MORTALITY; NAUSEA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SHORT FORM 36; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS CONTROL;

ADOLESCENT; ADULT; AGE FACTORS; ALGORITHMS; ANTITUBERCULAR AGENTS; BCG VACCINE; CANADA; CONTACT TRACING; DECISION SUPPORT TECHNIQUES; EMIGRANTS AND IMMIGRANTS; HEALTH POLICY; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MODELS, THEORETICAL; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; RISK ASSESSMENT; TIME FACTORS; TUBERCULIN TEST; YOUNG ADULT;

EID: 84872709574     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.09.006     Document Type: Article

References (51)

1. P.M. Small, and P.I. Fujiwara Management of tuberculosis in the United States N Engl J Med 345 2001 189 200
2. R. Long, H. Njoo, and E. Hershfield Tuberculosis: 3, epidemiology of the disease in Canada CMAJ 160 1999 1185 1190
3. Center for Disease Control and Prevention. Trends in tuberculosis - United States, 2005. MMWR Morb. Mortal Wkly Rep 2006 Mar 24;55:305-8.
4. American Thoracic Society Targeted tuberculin testing and treatment of latent tuberculosis infection MMWR Recomm Rep 49 2000 1 51
5. Canadian Tuberculosis Standards - 6th Edition 2007 - Public Health Agency of Canada. 2010. Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/ tbstand07-eng.php. [Accessed April 28, 2012].
6. H.L. Rieder Fourth-generation fluoroquinolones in tuberculosis Lancet 373 2009 1148 1149
7. American Thoracic Society, American Lung Association, Center for Disease Control. Preventive therapy of tuberculous infection Am Rev Respir Dis 110 1974 371 374
8. Bailey W, Albert R, Davidson P. Treatment of tuberculosis and other mycobacterial diseases Am Rev Respir Dis 127 1983 790 796
9. W.L. Holden, J. Juhaeri, and W. Dai Benefit-risk analysis: a proposal using quantitative methods Pharmacoepidemiol Drug Saf 12 2003 611 616
10. J.C. Felli, R.A. Noel, and P.A. Cavazzoni A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives Med Decis Making 29 2009 104 115
11. W.W. Stead, T. To, R.W. Harrison, and J.H. Abraham Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons Ann Intern Med 107 1987 843 845
12. S.A. Waldman, and A. Terzic Individualized medicine and the imperative of global health Clin Pharmacol Ther 82 2007 479 483
13. L.D. Lynd, and B.J. O'brien Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis J Clin Epidemiol 57 2004 795 803
14. O. Morán-Mendoza, S.A. Marion, and K. Elwood Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts Int J Tuberc Lung Dis 11 2007 1014 1020
15. D.E. Kopanoff, D.E. Snider, and G.J. Caras Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study Am Rev Respir Dis 117 1978 991 1001
16. F.F. Fountain, E. Tolley, C.R. Chrisman, and T.H. Self Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic Chest 128 2005 116 123
17. P.A. LoBue, and K.S. Moser Use of isoniazid for latent tuberculosis infection in a public health clinic Am J Respir Crit Care Med 168 2003 443 447
18. C.M. Nolan, S.V. Goldberg, and S.E. Buskin Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic JAMA 281 1999 1014 1018
19. S.R. Salpeter Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis West J Med 159 1993 560 564
20. N. Breslow Discussion of the paper by D. R. Cox J R Statist Soc B 34 1972 216 217
21. W.M. Lee Drug-induced hepatotoxicity N Engl J Med 349 2003 474 485
22. J.R. Mitchell, H.J. Zimmerman, and K.G. Ishak Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis Ann Intern Med 84 1976 181 192
23. M. Steele, R. Burk, and R. DesPrez Toxic hepatitis with isoniazid and rifampin: a meta-analysis Chest 99 1991 465 471
24. M.J. Smieja, C.A. Marchetti, D.J. Cook, and F.M. Smaill Isoniazid for preventing tuberculosis in non-HIV infected persons Cochrane Database Syst Rev 2 2000 CD001363
25. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial Bull World Health Organ 60 1982 555 564
26. ATS/CDC Statement Committee on Latent Tuberculosis Infection Membership List. Targeted tuberculin testing and treatment of latent tuberculosis infection. 2000. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/ rr4906a1.htm. [Accessed April 28, 2012].
27. D. Menzies, M.-J. Dion, and B. Rabinovitch Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months Am J Respir Crit Care Med 170 2004 445 449
28. R.M. Jasmer, D.C. Snyder, and D.P. Chin Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis Am J Respir Crit Care Med 162 2000 1648 1652
29. Statistics Canada. Life tables, Canada and provinces and territories. Available from: http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm. [Accessed April 28, 2012].
30. N. Guo, C.A. Marra, and F. Marra Health state utilities in latent and active tuberculosis Value Health 11 2008 1154 1161
31. C.A. Marra, F. Marra, and L. Colley Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection Chest 133 2008 396 403
32. K.A. Zug, B. Littenberg, and R.D. Baughman Assessing the preferences of patients with psoriasis: a quantitative, utility approach Arch Dermatol 131 1995 561 568
33. L. Longworth, and S. Bryan An empirical comparison of EQ-5D and SF-6D in liver transplant patients Health Econ 12 2003 1061 1067
34. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. Report No. 172chedp. York: Centre for Health Economics, University of York, 1999. Available from: http://ideas.repec.org/p/chy/respap/172chedp.html. [Accessed April 28, 2012].
35. N. Guo, F. Marra, and J.M. Fitzgerald Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis Eur Respir J 36 2010 206 208
36. W.M. Hopman, T. Towheed, and T. Anastassiades Canadian normative data for the SF-36 health survey CMA 163 2000 265 271
37. R. Ara Brazier J. Predicting the Short Form-6D preference-based index using the eight mean Short Form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available Value Health 12 2009 346 353
38. N. Guo, F. Marra, and C.A. Marra Measuring health-related quality of life in tuberculosis: a systematic review Health Qual Life Outcomes 7 2009 14
39. D. Chamla The assessment of patients' health-related quality of life during tuberculosis treatment in Wuhan, China Int J Tuberc Lung Dis 8 2004 1100 1106
40. B. Chang, A.W. Wu, N.N. Hansel, and G.B. Diette Quality of life in tuberculosis: a review of the English language literature Qual Life Res 13 2004 1633 1642
41. R. Marchand, P. Tousignant, and H. Chang Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly Int J Epidemiol 28 1999 563 570
42. L.P. Garrison, A. Towse, and B.W. Bresnahan Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis Health Aff (Millwood) 26 2007 684 695
43. P.D. Ziakas, and E. Mylonakis 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity Clin Infect Dis 49 2009 1883 1889
44. D.P. Holland, G.D. Sanders, C.D. Hamilton, and J.E. Stout Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection Am J Respir Crit Care Med 179 2009 1055 1060
45. S.-Y. Eum, Y.-J. Lee, and H.-K. Kwak Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in Bacille Calmette-Guerin (BCG)-vaccinated individuals Diagn Microbiol Infect Dis 61 2008 181 186
46. B.P. Linas, A.Y. Wong, K.A. Freedberg, and C.R. Horsburgh Jr Priorities for screening and treatment of latent tuberculosis infection in the United States Am J Respir Crit Care Med 184 2011 590 601
47. W.H. Shrank, A.R. Patrick, and M.A. Brookhart Healthy user and related biases in observational studies of preventive interventions: a primer for physicians J Gen Intern Med 26 2011 546 550
48. L. Wang, M. Turner, and R. Elwood A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements Thorax 57 2002 804 809
49. D. Menzies, G. Gardiner, and M. Farhat Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results Int J Tuberc Lung Dis 12 2008 498 505
50. H. McCallum, N. Barlow, and J. Hone How should pathogen transmission be modelled? Trends Ecol Evol 16 2001 295 300
51. K. Claxton The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies Health Econ Rev 18 1999 341 364